New inhaled therapy could help preterm infants breathe easier
NCT ID NCT06776783
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests a new inhaled medication called APC-0101 in 520 premature babies born between 26 and 33 weeks who have respiratory distress syndrome. The drug is a surfactant that helps keep tiny air sacs in the lungs open. Some babies receive the active drug through a special mask, while others get a sham treatment. The main goal is to see if APC-0101 reduces the need for more invasive breathing support.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
APC-0101 (inhaled surfactant)
What this could lead to
If successful, this could offer a gentler, non-invasive way to help preterm babies breathe, reducing the need for more invasive treatments.
What could go wrong
This is an early-stage Phase 3 trial, so results are not guaranteed. The sham-controlled design means some babies receive no active drug, and long-term effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY DISTRESS SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Advent Health
RECRUITINGOrlando, Florida, 32803, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Christus Children's Hospital
RECRUITINGSan Antonio, Texas, 78207, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Goryeb Children's Hospital
RECRUITINGMorristown, New Jersey, 07960, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Jacobs Medical Center
RECRUITINGLa Jolla, California, 92037, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Maria Farreri Children's Hospital
RECRUITINGValhalla, New York, 10595, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Memorial Hospital of South Bend
RECRUITINGSouth Bend, Indiana, 46601, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Montefiore Medical Center
RECRUITINGThe Bronx, New York, 10461, United States
Contact Email: •••••@•••••
-
The Trustees of Columbia University in the City of New York
RECRUITINGNew York, New York, 10032, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UF Health Jacksonville
RECRUITINGJacksonville, Florida, 32209, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Arkansas for Medical Sciences
RECRUITINGLittle Rock, Arkansas, 72205, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Virginia School of Medicine
RECRUITINGCharlottesville, Virginia, 22903, United States
Contact Email: •••••@•••••
-
WVU Medicine Children's Hospital
RECRUITINGMorgantown, West Virginia, 26506, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••